Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Clofazimine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 630Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MannKind Initiates Phase 3 Trial in Australia for NTM Lung Disease
    MannKind Initiates Phase 3 Trial in Australia for NTM Lung Disease

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972227/29517/en/First-Site-Initiated-in-Australia-for-MannKind-s-Phase-3-Clinical-Trial-Evaluating-Clofazimine-Inhalation-Suspension-for-the-Treatment-of-Nontuberculous-Mycobacterial-NTM-Lung-Dise.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    MannKind To Start Phase 3 NTM Trial In Japan
    MannKind To Start Phase 3 NTM Trial In Japan

    18 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/18/2948042/29517/en/MannKind-Announces-Clearance-from-PMDA-to-Initiate-Phase-3-Clinical-Trial-ICoN-1-in-Japan-Evaluating-Clofazimine-Inhalation-Suspension-for-the-Treatment-of-Nontuberculous-Mycobacte.html

    GLOBENEWSWIRE
    18 Sep 2024
    Share Share
    MannKind's Clofazimine Gets FDA Fast Track For NTM Lung Disease
    MannKind's Clofazimine Gets FDA Fast Track For NTM Lung Disease

    06 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/06/2875645/29517/en/MannKind-Receives-U-S-FDA-Fast-Track-Designation-for-Clofazimine-Inhalation-Suspension-for-the-Treatment-of-Nontuberculous-Mycobacterial-NTM-Lung-Disease.html

    GLOBENEWSWIRE
    06 May 2024
    Share Share
    MannKind Gets IND Clearance for Ph3 Clofazimine in NTM Lung Disease
    MannKind Gets IND Clearance for Ph3 Clofazimine in NTM Lung Disease

    29 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/29/2871043/29517/en/MannKind-Announces-IND-Clearance-From-U-S-FDA-to-Start-Phase-3-Study-of-Clofazimine-Inhalation-Suspension-for-Nontuberculous-Mycobacterial-NTM-Lung-Disease.html

    GLOBENEWSWIRE
    29 Apr 2024
    Share Share
    Midas Pharma obtains CEP for Clofazimine
    Midas Pharma obtains CEP for Clofazimine

    28 Dec 2021

    // PRESS RELEASE

    https://www.midas-pharma.com/en/latest-activities/midas-pharma-obtains-cep-for-clofazimine/

    PRESS RELEASE
    28 Dec 2021
    Share Share
    Could this low-cost leprosy drug be repurposed for COVID-19?
    Could this low-cost leprosy drug be repurposed for COVID-19?

    17 Mar 2021

    // Angus Liu FIERCEBIOTECH

    https://www.fiercebiotech.com/research/could-low-cost-leprosy-drug-clofazimine-be-repurposed-for-covid-19

    Angus Liu FIERCEBIOTECH
    17 Mar 2021
    Share Share